PROFOUND MEDICAL CORP. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PROFOUND MEDICAL CORP. (PROF) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$19.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$8.58M.
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$8.57M, a 153.83% decline year-over-year.
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $15.93M.
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $2.69M, a 91.39% decline from fiscal 2024.
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $31.24M.
- PROFOUND MEDICAL CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$20.85M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.92M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$8.58M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.69M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$31.93M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$22.32M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$8.57M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $31.24M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $1.69M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $9.11M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $15.93M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$20.85M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |